University of Alberta
- Country
- 🇨🇦Canada
- Ownership
- Private
- Established
- 1908-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.ualberta.ca
Clinical Trials
762
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (655 trials with phase data)• Click on a phase to view related trials
Adapting Rehabilitation Delivery for Maximum Impact at Home-2 (ReDI-2)
- Conditions
- Knee OsteoarthritisHip Osteoarthritis
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 270
- Registration Number
- NCT07055113
- Locations
- 🇨🇦
Edmonton Bone and Joint Centre, Edmonton, Alberta, Canada
Integrating Inuit Knowledge Principles in Multi-Level Mental Health Clinical Trials
- Conditions
- Depression, Anxiety
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 40
- Registration Number
- NCT07014852
- Locations
- 🇨🇦
Aqqiumavvik Society, Arviat, Nunavut, Canada
🇨🇦Aqqiumavvik - Arviat Wellness Society, Arviat, Nunavut, Canada
Effectiveness of Psychodermatologic Educational Modules on Atopic Dermatitis Patient Outcomes
- Conditions
- Atopic Dermatitis (AD)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 42
- Registration Number
- NCT07009483
- Locations
- 🇨🇦
Rao Dermatology, Edmonton, Alberta, Canada
🇨🇦Kaye Edmonton Clinic, Edmonton, Alberta, Canada
🇨🇦Stollery Children's Hospital, Edmonton, Alberta, Canada
Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy
- Conditions
- Hypogammaglobulinemia, Acquired
- Interventions
- Biological: Immune Globulin Intravenous (Human), 10%Biological: Immune Globulin Subcutaneous (Human), 20% Solution
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 30
- Registration Number
- NCT06989541
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Drug: PlaceboCombination Product: Treprostinil Inhalation Solution 36 mcgCombination Product: Treprostinil Inhalation Solution 78 mcg
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 20
- Registration Number
- NCT06969573
- Locations
- 🇨🇦
Clinical Physiology Laboratory, Edmonton, Alberta, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 153
- Next
News
Onco-Innovations Partners with University of Alberta to Advance PNKP Inhibitor Research for Glioblastoma Treatment
Onco-Innovations has entered into a research agreement with the University of Alberta and Cross Cancer Institute to expand preclinical studies of its PNKP inhibitor technology for hard-to-treat cancers, beginning with glioblastoma multiforme.
World-First Clinical Trial Demonstrates Exercise Significantly Improves Colon Cancer Survival
A groundbreaking 17-year international clinical trial involving 889 colon cancer patients shows that structured exercise programs reduce cancer recurrence risk by 28% and death risk by 37%.
Onco-Innovations Initiates Manufacturing of PNKP Inhibitor for Preclinical Testing
Onco-Innovations has partnered with Dalton Pharma Services to begin manufacturing 50 grams of their proprietary PNKP inhibitor A83B4C63 for preclinical testing.
University of Alberta's Novel Cancer Drug Zelenirstat Receives FDA Fast-Track Designation
University of Alberta researchers have developed Zelenirstat, an innovative oral cancer medication that works by preventing cancer cell spread and starving tumors.